EATRIS-CONNECT
Aim
Description
Since the establishment of EATRIS as an ERIC in 2014, the infrastructure has developed a growing portfolio of services and collaborative projects serving several user groups including industry (large pharma and SME), academia, research funders and patients. EATRIS has progressed from proposing a strong proof of concept service portfolio, to building and delivering innovative tools for translational research and is now advancing its strategy to further exploit these tools for the extended research and innovation community.
EATRIS-CONNECT will accelerate this strategy by focusing specifically on advancing the digital readiness of EATRIS to support biomedical challenges in Europe and provide translational solutions for the benefit of personalised medicine. Through curated access to novel digital tools and services, as well as node strengthening, EATRIS-CONNECT will equip EATRIS across the entire distributed research infrastructure to address bottlenecks and challenges for the application of digital solutions in the context of use. Moreover, the project will ensure this digital transformation is environmentally sound by improving energy, resource, and material efficiency, supporting the environmental goals of the European Green Deal.
The project will promote the cross-border alignment in the adoption and application of digital tools and help consolidate the European RI landscape by fostering interdisciplinary collaborations between cross-sector RI and exploring how RI can together unlock innovation in the digital domain.
EATRIS-CONNECT will provide the pathway for the evolution of EATRIS. All 14 national EATRIS nodes form the central pillar of EATRISCONNECT, facilitating the alignment of strategic national priorities across the infrastructure and empowering EATRIS widening nodes to strengthen their digital competencies, ultimately ensuring the long-term sustainability of EATRIS.
Lead partner
EATRIS ERIC (Netherlands)
Project partners
Servicio Madrileño de Salud (Spain), Palacký University Olomouc (Czechia), Itä-Suomen yliopisto (Finland), Zagreb Medical School (Croatia), Istituto Superiore di Sanita (Italy), INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (Portugal), Luxembourg Institute of Health (Luxembourg), University of Ljubljana (Slovenia), Sofia University St. Kliment Ohridski (Bulgaria), Universitetet I Oslo (Norway), Uppsala University (Sweden), Commissariat à l’énergie atomique et aux énergies alternatives (France), University of Helsinki (Finland), Stichting Health-ri (Netherlands), IRCCS Istituto di ricerche farmacologiche Mario Negri (Italy), Aibili Associacao Para (Portugal), The Provost, Fellows, Foundation Scholars, and other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (Ireland), Fundacio Hospital Universitari Vall d'Hebron – Institut de Recerca (Spain)
Further information about the project